Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label Study to Investigate the Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis

NCT03241446 is registered in ClinicalTrials.gov with Navidea Biopharmaceuticals as lead sponsor.

NCT NCT03241446
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03241446 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label Study to Investigate the Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis
Lead sponsor
Navidea Biopharmaceuticals
Phase
Phase 1
Overall status
Withdrawn
Start date
September 30, 2017
Completion date
March 31, 2018
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid